Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal...
6 insider purchases on record · latest filing 2025-12-31.
Insiders have also filed 18 sale transactions at IRD.